REVIEW Febuxostat is a non-purine selective inhibitor of xanthine oxidase. It works by non-competitively blocking the molybdenum pterin center which is the active site on xanthine oxidase. Xanthine oxidase is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, febuxostat inhibits xanthine oxidase, therefore reducing production of uric acid. Febuxostat inhibits both, oxidized as well as reduced form of xanthine oxidase because of which febuxostat cannot be easily displaced from the molybdenum pterin site.
REFERENCES
[1]
'Stamp LK, O''Donnell JL, Chapman PT (2007). Emerging therapies in the long-term management of hyperuricaemia and gout. Internal medicine journal 37 (4): 258-66. doi:10.1111/j.1445-5994.2007.01315.x. PMID 17388867.'
[2]
Adenuric (febuxostat) receives marketing authorisation in the European Union. Retrieved 2008-05-28.
[3]
Uloric Approved for Gout. U.S. News and World Report. Retrieved 2009-02-16.
[4]
Becker MA, Schumacher HR, Wortmann RL, et al. (December 2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353 (23): 2450-61. doi:10.1056/NEJMoa050373. PMID 16339094.
All products are stocked and shipped from San Francisco Bay Area, California, USA.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.